TL;DR
This study found that Hispanic patients with non-small cell lung cancer (NSCLC) in Los Angeles have a significantly higher incidence of anaplastic lymphoma kinase (ALK) alterations compared to non-Hispanic patients. This highlights the critical role of race and ethnicity in shaping molecular profiles of cancer and underscores the need for equitable access to comprehensive genomic profiling.
What Problem Does This Paper Address?
Lung cancer remains a leading cause of cancer-related deaths in the US. While advancements in targeted therapies, particularly for ALK-altered NSCLC, have dramatically improved patient outcomes, understanding the prevalence of these actionable alterations across different demographic groups is crucial for equitable care. Previous research has suggested that race and ethnicity can influence the distribution of molecular alterations in cancer. However, specific data on ALK alterations in the Hispanic population, which is the largest ethnic minority in the US, has been limited. This paper aims to fill this gap by investigating the real-world incidence of ALK alterations in Hispanic patients with NSCLC treated at a large academic institution in Los Angeles, a city with a significant Hispanic population. The study also seeks to explore potential factors contributing to observed differences in molecular profiles.
Methods
The researchers conducted a retrospective chart review of 607 patients diagnosed with non-small cell lung cancer (NSCLC) between January 2015 and June 2023 at two institutions: Los Angeles General Medical Center and the University of Southern California Norris Comprehensive Cancer Center. Patients included had confirmed NSCLC of adenocarcinoma, squamous, or large cell histology. Small cell lung cancer patients were excluded.
Molecular testing to identify actionable mutations was performed using either "a la carte" testing (individual gene tests like FISH or PCR for ALK) or comprehensive genomic profiling (CGP) via tissue or liquid biopsies. CGP involved advanced techniques like whole-exome and whole-transcriptome sequencing, as well as IHC for PD-L1 status.
Statistical analysis involved the Fisher exact test to compare the prevalence of ALK alterations between racial/ethnic groups and multivariate logistic regression to assess the independent effect of Hispanic ethnicity on ALK alteration incidence, while controlling for factors like treatment site, age at diagnosis, sex, and smoking history.
Datasets
The study utilized data from 607 NSCLC patients treated at the Los Angeles General Medical Center (LAG) and the University of Southern California Norris Comprehensive Cancer Center (Norris). Demographic data (age, sex, race/ethnicity, smoking history) and clinical characteristics (stage, histology, brain metastasis, presence of targetable mutations) were collected from electronic medical records. Additionally, the study referenced data from the U.S. Census Bureau and the California Cancer Registry for contextual information on population demographics.
Key Insights and Ideas
- Disproportionate ALK Alteration Incidence: The most striking finding is the significantly higher prevalence of ALK alterations in Hispanic patients with NSCLC compared to their non-Hispanic counterparts. This suggests that race and ethnicity are not just demographic markers but can be associated with distinct molecular landscapes in cancer.
- Impact of Race/Ethnicity on Molecular Profiles: This study reinforces the idea that genetic and potentially environmental factors linked to race and ethnicity play a role in the development and characteristics of NSCLC.
- Need for Equitable Genomic Profiling: The observed disparities highlight the importance of ensuring that all patient populations, especially underrepresented groups like Hispanics, have access to comprehensive genomic testing. This is crucial for identifying actionable mutations and tailoring treatment.
- Potential for Environmental and Biological Factors: While the study identifies a correlation, it also points to the complex interplay of factors, including environmental exposures and biological differences, that may contribute to these observed variations in ALK alteration prevalence.
Key Results
- A total of 607 NSCLC patients were analyzed.
- Hispanic patients had a significantly higher incidence of ALK alterations: 12.76% (18 out of 141) compared to non-Hispanic patients: 5.36% (25 out of 466) (P = 0.0046).
- Multivariate logistic regression identified Hispanic ethnicity as a significant independent predictor of ALK alteration incidence (HR, 2.393; 95% CI, 1.115-5.092).
- Age at diagnosis was also a significant variable, with older age associated with lower ALK alteration incidence (HR, 0.9325; 95% CI, 0.9081-0.9558).
- Among ALK-altered patients, Hispanic patients were more likely to be diagnosed with stage IV disease (94.44%) and have brain metastases (61.11%) compared to the overall ALK-altered population.
- The majority of ALK alterations (55.81%) were initially identified via comprehensive genomic profiling (NGS).
Limitations and Future Work
The authors acknowledge several limitations:
- Small Sample Size: The study included a relatively small number of patients with ALK alterations, which may limit the generalizability of the findings.
- Limited Variant Subtypes: The study could only document specific EML4-ALK variant subtypes for a subset of patients.
- Self-Reported Ethnicity: Reliance on self-reported ethnicity introduces the possibility of subjective reporting bias.
- Nativity and Residence Data: The study lacked detailed information on patients' country of birth and history of residence, which could provide further insights into environmental influences.
- Variability in Testing Methods: The use of different molecular testing methods (CGP vs. a la carte) may have contributed to variations in detected mutation incidence.
Future research directions suggested by the authors include:
- Larger, Diverse Cohorts: Investigating ALK alteration prevalence in a larger and more diverse patient cohort to confirm these findings.
- Detailed Demographic and Environmental Data: Collecting comprehensive data on country of birth, history of residence, and environmental exposures to better understand their impact.
- Tumor Microenvironment Analysis: Exploring the role of tumor microenvironments in ALK alteration prevalence, as this can influence treatment response and prognosis.
- Subgroup Analysis: Further analyzing distinct outcomes between different Hispanic subgroups to account for the heterogeneity within this population.
Summary updated